Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

Share this page:

Title

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

Subject

Description

Assessing the burden of COVID-19 on the basis of medically attended case numbers is suboptimal given its reliance on testing strategy, changing case definitions, and disease presentation. Population-based serosurveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies provide one method for estimating infection rates and monitoring the progression of the epidemic.

Date Last Updated (Year-Month-Day)

2020-06-11

Citation

Stringhini, Silvia, Ania Wisniak, Giovanni Piumatti, Andrew S. Azman, Stephen A. Lauer, Hélène Baysson, David De Ridder, Dusan Petrovic, Stephanie Schrempft, Kailing Marcus, Sabine Yerly, Isabelle Arm Vernez, Olivia Keiser, Samia Hurst, Klara M. Posfay-Barbe, Didier Trono, Didier Pittet, Laurent Gétaz, François Chappuis, Isabella Eckerle, Nicolas Vuilleumier, Benjamin Meyer, Antoine Flahault, Laurent Kaiser, and Idris Guessous. 2020. "Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study." The Lancet.

Accessibility

Free online on Lancet site.